Mechanistic SCFA Profiling for Neuroimmune Modulation Studies

SCFA production is highly strain-specific and incredibly sensitive to environmental conditions, carbon source availability, and growth phase. Generic literature can tell you that a species generally produces butyrate, but regulatory bodies and partners require specific, quantified evidence that your proprietary strain produces therapeutic levels of specific SCFAs under physiologically relevant conditions. Our analytical quantification provides this precise, foundational evidence.

Absolutely. In the gut microenvironment, neuroimmune cells are never exposed to a single SCFA in isolation. We can formulate precise physiological ratios of acetate, propionate, and butyrate—mimicking the exact ratios produced by your microbial candidate—and apply these defined mixtures to our neuroimmune models to observe synergistic or antagonistic immunomodulatory effects.

We utilize highly controlled experimental designs. First, we use targeted inhibitors for specific SCFA receptors (like GPR43/GPR41 antagonists) on the neuroimmune cells. If the immunomodulatory effect is lost when the receptor is blocked, it strongly implies an SCFA-driven mechanism. Additionally, we run parallel controls using synthetic SCFAs matched to the concentrations found in your strain's supernatant to isolate the metabolic effect from other secreted factors (like bacteriocins or extracellular vesicles).

Our optimized extraction protocols accommodate a wide variety of sample matrices. We routinely process in vitro bacterial culture supernatants, co-culture media, bioreactor sampling fluid, and in vivo matrices including fecal matter, cecal contents, and even serum or brain tissue homogenates (depending on the study design and required limits of detection).